• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis.

作者信息

Choden Tenzin, Yeager Mia, Cohen Russell D

机构信息

Department of Medicine, University of Chicago Inflammatory Bowel Disease Center, Chicago, IL, USA.

Department of Pathology, University of Chicago, Chicago, IL, USA.

出版信息

Dig Dis Sci. 2022 Nov;67(11):5010-5013. doi: 10.1007/s10620-022-07668-5. Epub 2022 Sep 13.

DOI:10.1007/s10620-022-07668-5
PMID:36098874
Abstract
摘要

相似文献

1
Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis.探究炎症性肠病与检查点抑制剂结肠炎之间的关联。
Dig Dis Sci. 2022 Nov;67(11):5010-5013. doi: 10.1007/s10620-022-07668-5. Epub 2022 Sep 13.
2
Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy.免疫细胞反应的药物特异性差异在免疫检查点抑制剂相关性结肠炎中显现，与炎症性肠病存在重叠，并可预测结肠炎治疗的反应。
Am J Clin Pathol. 2021 Jul 6;156(2):214-228. doi: 10.1093/ajcp/aqaa217.
3
Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.癌症合并炎症性肠病患者中免疫检查点抑制剂相关腹泻和结肠炎（imDC）的发生率：一项倾向评分匹配的回顾性研究。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002567.
4
[Effects of Pim-1 inhibitor on mouse model of inflammatory bowel disease induced by TNBS].Pim-1抑制剂对三硝基苯磺酸诱导的小鼠炎症性肠病模型的影响
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 May 28;43(5):481-489. doi: 10.11817/j.issn.1672-7347.2018.05.004.
5
Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.系统评价与荟萃分析：在有既往炎症性肠病的患者中使用免疫检查点抑制剂的安全性和耐受性。
Aliment Pharmacol Ther. 2021 Feb;53(3):374-382. doi: 10.1111/apt.16217. Epub 2020 Dec 12.
6
Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis.免疫检查点抑制剂相关结肠炎发病后溃疡性结肠炎恶化。
Clin J Gastroenterol. 2021 Feb;14(1):152-158. doi: 10.1007/s12328-020-01261-x. Epub 2020 Oct 14.
7
The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease.补体和接触系统在葡聚糖硫酸钠诱导的结肠炎模型中的作用：C1 抑制剂在炎症性肠病中的作用。
Am J Physiol Gastrointest Liver Physiol. 2010 Jun;298(6):G878-83. doi: 10.1152/ajpgi.00400.2009. Epub 2010 Mar 25.
8
A prospective study of first attacks of inflammatory bowel disease and non-relapsing colitis. Microbiologic findings.炎症性肠病首次发作和非复发性结肠炎的前瞻性研究。微生物学研究结果。
Scand J Gastroenterol. 1993 Dec;28(12):1077-85. doi: 10.3109/00365529309098313.
9
Inflammatory Bowel Disease-Mimicking Colitis Associated With Nintedanib-Based Therapy in a Lung Cancer Patient.一名肺癌患者中与基于尼达尼布的治疗相关的炎症性肠病样结肠炎
Int J Surg Pathol. 2023 Oct;31(7):1326-1328. doi: 10.1177/10668969221143472. Epub 2022 Dec 13.
10
Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease.血管活性肠肽纳米医学用于炎症性肠病的治疗。
Mol Pharm. 2017 Nov 6;14(11):3698-3708. doi: 10.1021/acs.molpharmaceut.7b00452. Epub 2017 Oct 19.

本文引用的文献

1
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：ASCO 指南更新。
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.
2
Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.癌症合并炎症性肠病患者中免疫检查点抑制剂相关腹泻和结肠炎（imDC）的发生率：一项倾向评分匹配的回顾性研究。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002567.
3
AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review.
AGA 临床实践更新：免疫检查点抑制剂相关性结肠炎和肝炎的诊断与管理：专家综述。
Gastroenterology. 2021 Mar;160(4):1384-1393. doi: 10.1053/j.gastro.2020.08.063. Epub 2020 Oct 17.
4
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.癌症免疫疗法诱导的结肠炎症的分子途径。
Cell. 2020 Aug 6;182(3):655-671.e22. doi: 10.1016/j.cell.2020.06.001. Epub 2020 Jun 29.
5
Checkpoint Inhibitor-Induced Colitis.免疫检查点抑制剂相关性结肠炎
Am J Gastroenterol. 2020 Feb;115(2):202-210. doi: 10.14309/ajg.0000000000000497.
6
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.免疫检查点抑制剂治疗伴有既往炎症性肠病的患者。
J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4.
7
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.免疫介导性结肠炎后免疫检查点抑制剂治疗的恢复。
J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4.
8
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.免疫检查点抑制剂诱导的结肠炎的内镜和组织学评估的重要性。
J Immunother Cancer. 2018 Sep 25;6(1):95. doi: 10.1186/s40425-018-0411-1.
9
Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?免疫检查点抑制剂能否诱发显微镜下结肠炎或全新实体？
Inflamm Bowel Dis. 2019 Jan 10;25(2):385-393. doi: 10.1093/ibd/izy240.
10
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.免疫检查点抑制剂相关性结肠炎的内镜和组织学特征。
Inflamm Bowel Dis. 2018 Jul 12;24(8):1695-1705. doi: 10.1093/ibd/izy104.